Browse the evidence

Antidiabetic medications impact skeletal muscle lipid metabolism.

Practitioners should consider the effects of antidiabetic medications on lipid metabolism when treating patients.

Current research has focused more on muscle mass than on skeletal muscle lipid metabolism.

Researchers should shift focus to skeletal muscle lipid metabolism in future studies.

Research in the area of nutrigenomics and lifestyle genomics for weight management is promising but limited.

Further research is needed to validate the effectiveness of these interventions.

Specific limitations in the studies include small sample sizes and methodological issues.

Researchers should address these limitations in future studies to improve the validity of findings.

Compounds K2 and K5 decreased and maintained the body weight of diet-induced obese mice.

Compounds K2 and K5 may be potential candidates for drug development targeting obesity.

The study proposes an approach for treating overweight and obese patients by preventing or reducing CCK1 activation.

This approach may inform future obesity treatments focusing on CCK1 regulation.

The goal to reduce the incidence rate of overweight and obese active duty military service members by 5% was not achieved, and the rate of overweight and obese increased by 1.57% over the 6-month period.

Practitioners should be aware that current interventions may not be effective in reducing obesity rates in military populations.

There were decreases in the normal weight category with an increase in the overweight and obesity rate.

This indicates a need for targeted interventions to address weight management in military personnel.

Total physical activity was similar in dog owners with type 1 diabetes (T1D) compared to non-dog owners.

Dog ownership may not significantly enhance physical activity in T1D patients.

Delayed onset muscle soreness (DOMS) was lower in the naproxen group, but differences were not statistically significant.

Naproxen may help reduce muscle soreness post-exercise, though not significantly.

There is a weak positive association between BMI and KIDMED index in the physically active population, which was not statistically significant.

Practitioners should be cautious in interpreting the relationship between BMI and nutritional status.

Peanut hulls are an underutilized food source for human consumption that can improve nutrient-density in common foods.

Incorporating peanut hulls into foods can enhance their nutritional value.

Valorizing peanut hulls can address food waste and improve food security.

Utilizing peanut hulls can contribute to reducing food waste and enhancing food security.

Recent advances in sustainable food processing technologies can safely incorporate peanut hulls into human food streams.

Innovative processing technologies can enable the use of peanut hulls in food products.

Metformin may have a role in primary and secondary prevention of cardiovascular disease.

Practitioners may consider metformin for cardiovascular disease prevention in diabetic patients.

Sodium-glucose transporter 2 inhibitors have a role in both primary and secondary prevention of heart failure.

Sodium-glucose transporter 2 inhibitors may be beneficial for preventing heart failure in diabetic patients.

Whole-fat dairy may negatively impact cardiovascular disease (CVD) risk.

Caution may be warranted when recommending whole-fat dairy for cardiovascular health.

Only 6.2% of Canadians with stroke met both moderate-vigorous physical activity (MVPA) and muscle-strengthening activity (MSA) guidelines.

Clinicians should focus on increasing physical activity among stroke patients.

88.2% of Canadians with stroke engaged in MVPA less than 3 times per week.

Encouragement for more frequent MVPA is necessary for stroke patients.

76.7% of Canadians with stroke never engaged in muscle-strengthening activities (MSA).

There is a need to promote MSA among stroke patients.

The median risk ratio estimated by participants for the overweight-mortality association was 1.59, indicating a perceived 59% increased mortality risk.

Practitioners can use this risk ratio to inform discussions with patients about the health risks of being overweight.

Nearly all providers believe treating obesity improves quality of life (99%) and survival (95%) after lung transplantation.

Practitioners should recognize the strong belief among providers that obesity management is crucial for lung transplant recipients.

Only 41% of patients attempting weight loss are successful according to provider beliefs.

Practitioners should be aware of the low success rate in weight loss efforts among lung transplant recipients.

There is a gap between general obesity treatment guidelines and lung transplant practice.

Practitioners may need additional training and education to align their practices with obesity treatment guidelines.